Ciputra A Hartana, Ph.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Perforin | 2 | 2018 | 171 | 1.360 |
Why?
|
Urinary Bladder Neoplasms | 6 | 2018 | 2029 | 0.880 |
Why?
|
HIV-1 | 3 | 2022 | 6757 | 0.760 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2022 | 4254 | 0.700 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2018 | 77 | 0.670 |
Why?
|
HIV Seropositivity | 1 | 2022 | 893 | 0.630 |
Why?
|
Myeloid Cells | 1 | 2021 | 787 | 0.590 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2018 | 1164 | 0.520 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2016 | 654 | 0.440 |
Why?
|
HIV Infections | 3 | 2022 | 15538 | 0.430 |
Why?
|
Immunologic Memory | 1 | 2018 | 1391 | 0.420 |
Why?
|
Dendritic Cells | 1 | 2021 | 2726 | 0.380 |
Why?
|
DNA Methylation | 2 | 2018 | 4099 | 0.330 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2022 | 4383 | 0.310 |
Why?
|
Flow Cytometry | 1 | 2016 | 6127 | 0.280 |
Why?
|
MicroRNAs | 1 | 2021 | 3655 | 0.270 |
Why?
|
Carcinoma, Renal Cell | 1 | 2016 | 2910 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8638 | 0.220 |
Why?
|
Proviruses | 1 | 2021 | 272 | 0.200 |
Why?
|
Kidney Neoplasms | 1 | 2016 | 3970 | 0.190 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 489 | 0.180 |
Why?
|
Signal Transduction | 2 | 2021 | 23950 | 0.170 |
Why?
|
Interleukin-15 | 1 | 2018 | 166 | 0.170 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 821 | 0.160 |
Why?
|
Germinal Center | 1 | 2020 | 363 | 0.160 |
Why?
|
Hematoxylin | 1 | 2016 | 63 | 0.160 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2016 | 73 | 0.160 |
Why?
|
Glycolysis | 1 | 2021 | 815 | 0.160 |
Why?
|
Keratin-18 | 1 | 2016 | 40 | 0.160 |
Why?
|
Urothelium | 1 | 2018 | 285 | 0.150 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2018 | 474 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 1060 | 0.140 |
Why?
|
Adenoma, Oxyphilic | 1 | 2016 | 134 | 0.140 |
Why?
|
False Negative Reactions | 1 | 2016 | 610 | 0.140 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2022 | 1418 | 0.140 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2020 | 997 | 0.130 |
Why?
|
Killer Cells, Natural | 1 | 2022 | 2165 | 0.120 |
Why?
|
Viral Load | 1 | 2021 | 3231 | 0.110 |
Why?
|
Antigens, Neoplasm | 2 | 2019 | 2003 | 0.110 |
Why?
|
Urinary Bladder | 1 | 2018 | 1125 | 0.110 |
Why?
|
Staining and Labeling | 1 | 2016 | 1151 | 0.110 |
Why?
|
Cadherins | 1 | 2016 | 921 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1017 | 0.100 |
Why?
|
Neoadjuvant Therapy | 2 | 2018 | 2561 | 0.100 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 3464 | 0.100 |
Why?
|
Alleles | 1 | 2022 | 7090 | 0.100 |
Why?
|
Immunity, Innate | 1 | 2022 | 2937 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2022 | 2768 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 1924 | 0.090 |
Why?
|
Lymphocyte Activation | 2 | 2018 | 5908 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2016 | 2951 | 0.090 |
Why?
|
Cells, Cultured | 3 | 2018 | 20170 | 0.080 |
Why?
|
B-Lymphocytes | 2 | 2020 | 4861 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4926 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11253 | 0.070 |
Why?
|
Tumor Escape | 2 | 2019 | 328 | 0.070 |
Why?
|
Immunotherapy | 2 | 2018 | 4057 | 0.070 |
Why?
|
Humans | 13 | 2022 | 708843 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3055 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3773 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2020 | 58184 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 3876 | 0.060 |
Why?
|
Infant, Newborn | 1 | 2022 | 24433 | 0.060 |
Why?
|
Aged | 7 | 2020 | 161488 | 0.060 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3153 | 0.060 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3275 | 0.050 |
Why?
|
Male | 8 | 2021 | 349524 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10362 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14836 | 0.050 |
Why?
|
Female | 8 | 2021 | 375205 | 0.050 |
Why?
|
Middle Aged | 7 | 2020 | 213752 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 200 | 0.050 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 16959 | 0.050 |
Why?
|
Prospective Studies | 2 | 2018 | 50597 | 0.040 |
Why?
|
Muscle Neoplasms | 1 | 2018 | 146 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2020 | 4466 | 0.040 |
Why?
|
Interleukin-13 | 1 | 2018 | 365 | 0.040 |
Why?
|
Sweden | 1 | 2018 | 1290 | 0.040 |
Why?
|
Drug Therapy | 1 | 2018 | 518 | 0.030 |
Why?
|
Spleen | 1 | 2020 | 2473 | 0.030 |
Why?
|
CpG Islands | 1 | 2018 | 1177 | 0.030 |
Why?
|
Cystectomy | 1 | 2018 | 628 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2016 | 981 | 0.030 |
Why?
|
Interleukin-17 | 1 | 2018 | 894 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2016 | 1213 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2018 | 1600 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2016 | 1303 | 0.030 |
Why?
|
Neoplasms | 1 | 2019 | 20172 | 0.030 |
Why?
|
Down-Regulation | 1 | 2018 | 3093 | 0.020 |
Why?
|
Doxorubicin | 1 | 2016 | 2235 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2018 | 3245 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3515 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3693 | 0.020 |
Why?
|
Cell Lineage | 1 | 2018 | 2630 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11126 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 9488 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2018 | 61932 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 7089 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2018 | 11718 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2018 | 21194 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 28919 | 0.010 |
Why?
|
Time Factors | 1 | 2018 | 41038 | 0.010 |
Why?
|
Animals | 1 | 2019 | 170486 | 0.000 |
Why?
|